about
Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90Is NF-kappaB a good target for cancer therapy? Hopes and pitfallsPrevalence of monoclonal gammopathy of undetermined significance: a systematic reviewMonoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategiesSecond malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceClonogenic multiple myeloma progenitors, stem cell properties, and drug resistanceMonoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyMultiple myelomaSerum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceHigh serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisProblems monitoring response in multiple myelomaClinical use and applications of histone deacetylase inhibitors in multiple myelomaEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityThe 3' to 5' Exoribonuclease DIS3: From Structure and Mechanisms to Biological Functions and Role in Human DiseasePotential role of daratumumab in the treatment of multiple myelomaCurrent and emerging treatment options for patients with relapsed myelomaDefining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasiasMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceThe European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human useEpigenetic dysregulation of Wnt signaling pathway in multiple myelomaDNA repair genes polymorphisms in multiple myeloma: no association with XRCC1 (Arg399Gln) polymorphism, but the XRCC4 (VNTR in intron 3 and G-1394T) and XPD (Lys751Gln) polymorphisms is associated with the disease in Turkish patientsInhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signalingSmall compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myelomaTargeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivoPhenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myelomaNeovascular niche for human myeloma cells in immunodeficient mouse boneHigh throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomibCommon variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskCommon variation at 3p22.1 and 7p15.3 influences multiple myeloma riskMaintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.Shear flow-induced formation of tubular cell protrusions in multiple myeloma cells.Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) magnetic resonance imaging as a biomarker for symptomatic multiple myeloma.Metabolic profiling-based data-mining for an effective chemical combination to induce apoptosis of cancer cells.Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.
P2860
Q24336102-9745621E-18E7-47C5-867C-0B4416008590Q24570128-653E3EAC-2C2A-4429-B112-CE16BB535406Q24597406-515E336C-77FC-4FC0-9DD2-BD382621DE8EQ24607241-85D57E72-49F6-49E8-9FF9-5BA9B245225FQ24610430-134B4AE7-F48B-43E2-8C45-6A0957E4DF75Q24644883-C7ED8AB8-621E-4515-9178-80A7A2F35761Q24653006-959BCE6B-497C-4571-812B-C4168FECBFF0Q24655964-388558EE-1517-4944-9930-A96F475F5133Q24669898-5A4D9794-3B7E-4DF8-955A-817FFFE75106Q24670135-3BA46862-EDEA-4984-BE84-DB778BF52041Q24676888-DE6F17F9-501D-4008-8B37-2ACCF6D889E7Q26745930-B04CEC2F-3216-4311-AC7E-7EC1FD274F9AQ26771331-3EDCFBEE-125C-4C08-8256-466C07D13710Q26801730-3C51EAB1-9732-4307-A94B-0B5695C1175CQ26824157-2CE51E61-55AA-491F-B161-50533D305138Q26830878-05553D46-F7FA-4CDE-9723-B27E1B58F101Q26861037-14B7BFDA-35EF-4A70-A7CD-F4DAE28351E9Q26998884-E6519012-5DA8-4D25-8092-B28D286A8D27Q27002668-3F95C636-B901-4665-9441-FE358D04D78BQ27004421-913D682C-52CD-4CF2-922D-B51DE5F9D3F8Q28077567-1033FC24-A1BE-444C-AC91-83C19CEC1309Q28084478-A09485A1-B4F6-42FB-9179-F128ADBF60A2Q28249838-1DD480F6-0DB8-4658-9319-83AE0F33A2C5Q28255746-7686A60A-BF79-49AB-BE30-4361022E4F15Q28474092-1E2CB4E9-29FD-4A8A-B84C-9DA02DF33AB8Q28478936-B481208D-FC8D-4B67-9C4C-82740672B5BAQ28483760-C732EA0B-27C9-48D1-90D6-14A7E50F08C5Q28731827-1050B3B3-BDD1-48CE-9371-A0C6A7B2D3D0Q28732210-A7F43F0D-452A-4BE0-8795-5F133448A753Q28818948-04AD9B43-E78E-4DEF-939C-FC18936A2AAFQ28943335-022B33B7-9125-4A87-A83C-C7E5441A31D2Q28943395-73542783-EB42-496C-B6A5-9425156B155CQ30275382-7677171F-98FF-44E1-9893-B14E9DFA021DQ30487339-25D1F6D2-9B19-481C-8852-9EB668D7CAFBQ30488936-997BDECB-D64E-4144-B0D0-0E579A419ABFQ30501430-67A067D2-A984-4261-A263-F315948444BEQ30897960-F956C62B-A3D4-4762-B2F1-E8B492F453DEQ30919523-20DA7D46-7170-4482-BDDA-648E6D4B3372Q31028788-9D7245FF-CD2E-4199-B10C-735AB50C9E7EQ33275167-9AD5C27A-1B17-4815-A180-84D897A7991A
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Multiple myeloma.
@ast
Multiple myeloma.
@en
Multiple myeloma.
@nl
type
label
Multiple myeloma.
@ast
Multiple myeloma.
@en
Multiple myeloma.
@nl
prefLabel
Multiple myeloma.
@ast
Multiple myeloma.
@en
Multiple myeloma.
@nl
P356
P1476
Multiple myeloma.
@en
P2093
Robert A Kyle
P304
P356
10.1056/NEJMRA041875
P407
P577
2004-10-01T00:00:00Z